The online-only Data Supplement is available at http://circheartfailure.ahajournals.org/lookup/suppl/Background-Cardiac dysfunction with sepsis is associated with both inflammation and reduced fatty acid oxidation. We hypothesized that energy deprivation accounts for sepsis-related cardiac dysfunction. Methods and Results-Escherichia coli lipopolysaccharide (LPS) administered to C57BL/6 mice (wild type) induced cardiac dysfunction and reduced fatty acid oxidation and mRNA levels of peroxisome proliferator-activated receptor (PPAR)-α and its downstream targets within 6-8 hours. Transgenic mice in which cardiomyocyte-specific expression of PPARγ is driven by the α-myosin heavy chain promoter (αMHC-PPARγ) were protected from LPS-induced cardiac dysfunction. Despite a reduction in PPARα, fatty acid oxidation and associated genes were not decreased in hearts of LPS-treated αMHC-PPARγ mice. LPS treatment, however, continued to induce inflammation-related genes, such as interleukin-1α, interleukin-1β, interleukin-6, and tumor necrosis factor-α in hearts of αMHC-PPARγ mice. Treatment of wild-type mice with LPS and the PPARγ agonist, rosiglitazone, but not the PPARα agonist (WY-14643), increased fatty acid oxidation, prevented LPS-mediated reduction of mitochondria, and treated cardiac dysfunction, as well as it improved survival, despite continued increases in the expression of cardiac inflammatory markers.
I mpaired cardiac contractility contributes to the hypotension and increased mortality that occur with sepsis. 1 A possible cause of sepsis-mediated cardiac dysfunction is reduced energy production in part because of compromised fatty acid oxidation (FAO) [2] [3] [4] [5] and glucose catabolism. 3, 6 Thus, it is likely that sepsis compromises cardiac energy production, which might be the major cause of cardiac dysfunction. Alternatively, sepsis induces the production of inflammatory cytokines, such as tumor necrosis factor-α, interleukin (IL)-1, and IL-6, and these might directly alter heart function. [7] [8] [9] Clinical Perspective on p 562
Intraperitoneal injection of lipopolysaccharide (LPS) has been extensively used to model many of the clinical features of sepsis, including elevated inflammation and cardiac dysfunction. 10 LPS leads to production of inflammatory cytokines [7] [8] [9] 11 and also reduces cardiac energy usage. 2, 3, 12 Nuclear receptors, particularly peroxisomal proliferatoractivated receptors (PPARs), regulate cardiac FAO. The PPAR family consists of 3 members: PPARα, PPARδ, and PPARγ. PPARα increases fatty acid storage in triglycerides 13 and FAO in heart 14 and induces expression of peroxisomal and mitochondrial enzymes. Besides PPARα, cardiac FAO can be increased by activation of PPARγ 15 or PPARδ. 16 Cardiomyocyte-specific overexpression of PPARα 14 or PPARγ 17 leads to cardiac lipid accumulation, an indication that lipid uptake exceeds FAO. PPARγ-coactivator-1 (PGC-1) α and β 18 enhance FAO and mitochondrial biogenesis. 19 Both PPARα and PGC-1 mRNA levels are markedly reduced in the heart by LPS administration, 2, 3, 12, 20 whereas PPARγ is not affected. 2 Our group showed that maintenance of normal cardiac FAO via c-Jun-N-terminal kinase inhibitor-mediated prevention of PPARα downregulation rescued cardiac function in septic mice, despite elevated expression of cardiac inflammatory markers. In a similar context, constitutive cardiac expression of PGC-1β prevented cardiac dysfunction that was caused by LPS-mediated sepsis, 3 an observation that was proposed to be because of improvement in cardiac FAO and attenuation of reactive oxygen species production. In the current study, we show that constitutive cardiomyocyte-specific expression of PPARγ or systemic administration of the PPARγ agonist, rosiglitazone, increased cardiac FAO and prevented cardiac dysfunction in mice with LPS-induced sepsis, despite increased expression of cardiac inflammatory markers. In addition, we show that rosiglitazone-mediated activation of PPARγ prevents the loss of cardiac mitochondria that occurs in sepsis. Moreover, we show that restoration of cardiac FAO by rosiglitazone not only prevents but also treats LPS-induced heart dysfunction and improves survival. Thus, the use of rosiglitazone is proposed as a potential treatment for septic cardiac dysfunction.
Methods
An expanded Methods appears in the online-only Data Supplement. All procedures involving animals were approved by the Institutional Animal Care and Use Committee at Columbia University. Briefly, this study included intraperitoneal administration of LPS in mice for induction of sepsis. Cardiac function was assessed by 2-dimensional (2D) echocardiography that was performed 6 to 8 hours post-LPS administration. Mice were euthanized and pieces of myocardium were obtained for gene expression and protein analysis, measurement of fatty acid oxidation, glucose oxidation, mitochondrial enzymes' activity, and ATP levels. Plasma and cardiac lipids were measured by enzymatic assays. Cardiac ceramide content was assessed by liquid chromatography and in tandem mass spectrometry, and cardiac mitochondrial number and size were analyzed by electron microscopy and mitochondrial ATPase 6 DNA copy number measurement. Survival studies were performed >72 hours and included a single intraperitoneal administration of a lethal dose of LPS and daily injections of rosiglitazone.
Statistical Analysis
Comparisons between 2 groups were performed using unpaired 2-tailed Student t tests. Comparisons between mean values of ≥3 groups were performed using 1-way ANOVA followed by Bonferroni post hoc tests, performing all pairwise comparisons. All values are presented as mean±SE. Survival was assessed by the Kaplan-Meier method and compared between groups using the Mantel-Cox log rank test. Differences were considered statistically significant at P<0.05.
Results

LPS-Mediated Sepsis Compromised Cardiac Function and FAO
Several studies 2, 3, 12, [20] [21] [22] have shown that administration of LPS in mice reduces cardiac PPARα mRNA levels, 3, 12, [20] [21] [22] which may account for the reduction of cardiac FAO. We confirmed that LPS administration reduced both cardiac PPARα mRNA levels by 75% (saline, 1.04±0.08; LPS, 0.25±0.03; P<0.0001; n=7) and heart function by 40% as shown by fractional shortening levels in C57BL/6 mice (saline, 44.3±2.1%; LPS, 25.9±2.1%; P<0.0001; n=7). Compromised cardiac function was associated with reduced cardiac FAO (Figure 1A) and ATP ( Figure 1B ) levels, as well as with increased phosphorylation of adenosine monophosphate kinase (AMPK; Figure 1C ; Figure I in the online-only Data Supplement). Heart:body weight and lung:body weight ratios were not increased by LPS ( Figure IIA and IIB in the online-only Data Supplement).
Administration of PPARα Agonist Does Not Rescue LPS-Driven Cardiac Dysfunction and Inhibition of FAO-Related Gene Expression
To test whether PPARα agonists would alleviate septic cardiac dysfunction, C57BL/6 mice were treated with combination of LPS (5 mg/kg) and the PPARα agonist, WY-14643 (30 mg/ kg). Administration of WY-14643 alone improved fractional shortening (43%) as compared with control saline-treated mice ( Figure IIIA and IIIB in the online-only Data Supplement). However, administration of WY-14643 in LPS-treated mice did not prevent cardiac dysfunction ( Figure IIIA and IIIB in the online Data Supplement). In addition, although WY-14643 alone stimulated the expression of fatty acid metabolism-related genes, such as cluster of differentiation (CD)-36, PGC-1α, and PGC-1β, it did not prevent their downregulation by LPS. Moreover, WY-14643 did not prevent the LPS-mediated changes of PPARα, ERRα (estrogen-related receptor-α), carnitine palmitoyl transferase (Cpt)-1β, acyl-CoA oxidase (AOX), perilipin (PLIN)-2, and PDK4 mRNA levels ( Figure 1E ). Thus, administration of PPARα agonist cannot prevent cardiac dysfunction that occurs in sepsis, which might be because of the profound reduction of PPARα gene expression levels and eventually to weak PPARα activation by its agonist.
Constitutive Cardiomyocyte-Specific Expression of PPARγ Prevents Reduction of Cardiac FAO in LPS-Treated Mice, Despite PPARα Downregulation
In order to assess whether PPARγ overexpression can compensate for the LPS-associated reduction of PPARα and can rescue FAO and cardiac function, we administered 5 mg/ kg LPS to mice with constitutive expression of PPARγ in cardiomyocytes (αMHC-PPARγ). 17 Treatment of αMHC-PPARγ mice with LPS activated (increased phosphorylation) Jun-N-terminal kinase ( Figure 1D ; Figure IV in the onlineonly Data Supplement) and reduced PPARα mRNA levels ( Figure 1F ), as was found in wild-type (WT) mice. However, cardiac function of the LPS-treated αMHC-PPARγ mice was not reduced. Specifically, 2D echocardiography (Figure 1G) showed fractional shortening levels in LPS-treated αMHC-PPARγ mice that were comparable to saline-treated αMHC-PPARγ and WT ( Figure 1H ). Thus, constitutive cardiomyocyte PPARγ expression prevented LPS-mediated cardiac dysfunction.
Opposite to the inhibitory effect of LPS on energy production in WT mice ( Figure 1A and 1B), the levels of cardiac FAO ( Figure 1I ) and ATP ( Figure 1J ) were not reduced in LPS-treated αMHC-PPARγ mice as compared with saline-treated αMHC-PPARγ mice. Phosphorylated AMPK levels were reduced in the LPS-treated αMHC-PPARγ mice, as compared with saline-treated αMHC-PPARγ mice ( Figure 1D ; Figure IV in the online-only Data Supplement). Accordingly, the inhibitory effect of LPS on FAO-associated gene expression levels, which was observed in WT mice 2, 3, 12, 20 was ablated in septic αMHC-PPARγ mice. Specifically, AOX, PPARδ, PGC-1α, and Cpt-1β mRNA levels were increased >10-fold each as compared with salinetreated αMHC-PPARγ mice ( Figure 1F ). αMHC-PPARγ mice have increased cardiac expression of AOX (3.5-fold) 17 and Cpt-1β (30%), 17 whereas PPARα, PPARδ, and PGC-1α are not significantly altered, as compared with wild-type mice ( Table I in the online-only Data Supplement). These changes occurred despite a reduced cardiac PGC-1β mRNA (76%; Figure 1F ), perhaps because of PGC-1α compensation. Pyruvate dehydrogenase kinase-4 (PDK4) mRNA levels were increased by 5.4-fold in the hearts of LPS-treated αMHC-PPARγ ( Figure 1F ), suggesting that preserved cardiac function was unlikely because of greater glucose usage. Basal PDK4 gene expression levels are 50% lower in αMHC-PPARγ mice, as compared with wild-type mice ( Table I in 
Cardiac Triglyceride Stores Are Not Increased in LPS-Treated αMHC-PPARγ Mice
Septic mice have increased cardiac triglyceride (TG) content, 3 perhaps as a consequence to increased plasma free fatty acid (FFA) and triglyceride levels 23, 24 and reduced cardiac fatty acid usage. We confirmed that LPS treatment led to accumulation of TGs in the hearts of C57BL/6 mice ( Figure 2A ), and this increase was associated with elevated plasma TG (Figure 2B) and FFA levels ( Figure 2C ). However, LPS-treated αMHC-PPARγ mice did not show either cardiac ( Figure 2D ) or plasma ( Figure 2E ) TG increases. Plasma FFA levels were increased in LPS-treated αMHC-PPARγ mice ( Figure 2F ). This was likely because of balanced lipid uptake and FAO. Consistent with the lack of change in stored TG, the expression levels of genes that are associated with lipid uptake and storage were not increased in LPS-treated αMHC-PPARγ mice. LPS reduced mRNA levels of CD36 and fatty acid transport protein-1 (FATP) in both WT ( Figure 2G ) and αMHC-PPARγ ( Figure 2H ) LPS-treated mice. Basal CD36 and FATP expression levels are 50% higher 17 and 50% lower ( Table I in the online-only Data Supplement), respectively, in αMHC-PPARγ mice as compared with wild-type mice. Although lipoprotein lipase (LpL) gene expression levels were reduced in WT mice ( Figure 2G ), they were not significantly affected by LPS treatment in αMHC-PPARγ mice ( Figure 2H ), which have similar lipoprotein lipase basal gene expression levels, as compared with WT mice ( Table I in the online-only Data Supplement). Angiopoietin-like protein-4 (Angptl4), which inhibits lipoprotein lipase activity, 25 was increased in both WT ( Figure 2G ) and αMHC-PPARγ ( Figure 2H ) mice that were treated with LPS. The change in Angptl4 gene expression levels may account for the reported LPS-mediated suppression of cardiac lipoprotein lipase activity. 21 These changes might have modified the expected greater uptake because of increased circulating TG and FFA levels. Accordingly, gene expression levels of perilipin (PLIN), which is associated with lipid droplet formation, were not modulated in the hearts of LPS-treated αMHC-PPARγ mice ( Figure 2H ), although cardiac PLIN2 mRNA levels were dramatically increased (7.7-fold) in the hearts of LPS-treated WT mice ( Figure 2G ). The expression levels of another lipid droplet-associated protein PLIN5, which might reduce fatty acid catabolism, 26 were not modulated in LPS-treated WT ( Figure 2G ) mice but decreased (50%) in αMHC-PPARγ mice treated with LPS ( Figure 2H ). Thus, although LPS-treated WT mice accumulate lipid droplets associated with decreased FAO and expression of PLIN2, LPS did not alter the balance among lipid uptake, oxidation, and storage in mice with constitutive expression of PPARγ in cardiomyocytes and did not induce cardiac dysfunction.
Prevention of LPS-induced Cardiac Dysfunction in αMHC-PPARγ Mice Was Not Associated With Alleviation of Inflammation
Inflammation is a major component of sepsis and its alleviation has been proposed as a therapeutic approach in sepsis based on studies in animal models with deletions of inflammation-related genes. [7] [8] [9] 11 However, prevention of LPS-related cardiac dysfunction in αMHC-PPARγ mice was not accompanied by alleviation of cardiac inflammation, as shown by cardiac mRNA levels of IL-1α, IL-1β, IL-6, and tumor necrosis factor-α ( Figure 1K ) that were elevated by >10-fold by LPS treatment. Thus, the beneficial effect of PPARγ in the prevention of cardiac dysfunction during sepsis cannot be accounted for by direct anti-inflammatory effects on the heart.
Pharmacological Activation of PPARγ Improves Cardiac FAO and Prevents Heart Dysfunction in LPS-Treated C57BL/6 Mice
To assess whether pharmacological activation of PPARγ prevents septic cardiac dysfunction, WT mice were treated intraperitoneally with the PPARγ agonist, rosiglitazone (30 mg/ kg), 30 minutes before the administration of LPS. Although LPS treatment activated Jun-N-terminal kinase ( Figure 3A ; Figure V in the online-only Data Supplement) and reduced PPARα mRNA levels in both control saline-treated and rosiglitazone-treated animals, rosiglitazone prevented LPSmediated cardiac dysfunction ( Figure 3B -3D). Rosiglitazone treatment did not prevent increases in plasma TG ( Figure 2B ) and FFA ( Figure 2C ) levels, which usually occur by LPS treatment. 23, 24 Opposite to the LPS-treated mice, cardiac FAO (Figure 1A) , and ATP levels ( Figure 1B) were not reduced in mice receiving both LPS and rosiglitazone.
The expression profile of several FAO-related genes correlated with the prevention of LPS-mediated suppression of FAO and was similar to the changes found in the LPStreated αMHC-PPARγ mice. Although PPARα mRNA levels were reduced (75%) by treatment of WT mice with LPS ( Figure 3D ), as they were in αMHC-PPARγ mice, Cpt-1β mRNA was increased by 35% ( Figure 3D ) and Cpt activity tended to increase in rosiglitazone-treated septic mice as compared with LPS-treated mice (saline, 2.02±0.54; Rosi, 1.49±0.36; LPS, 1.09±0.18*; LPS+Rosi, 1.61±0.49 nmol/ min per mg; n=5; *P<0.05 versus saline). Similarly, mediumand very long-chain acyl-CoA dehydrogenase (MCAD and VLCAD) mRNA levels were reduced by 30% and 25%, respectively, in LPS-treated mice, whereas they were not affected in mice treated with LPS and rosiglitazone ( Figure  VI 
Prevention of LPS-Induced Cardiac Dysfunction by PPARγ Agonist Was Not Associated With Alleviation of Cardiac Inflammation
Although PPARγ activation exerts anti-inflammatory effects by inhibiting the expression of proinflammatory genes in macrophages, 27 rosiglitazone-mediated improvement of cardiac function in LPS-treated WT mice was not because of attenuation of cardiac inflammation. Specifically, injection of rosiglitazone in LPS-treated mice did not prevent the increases in IL-1α, IL-1β, IL-6, and tumor necrosis factor-α gene expression levels ( Figure 3E) . Thus, the improvement in cardiac function by rosiglitazone was not associated with attenuation of expression of LPS-triggered inflammatory markers in the hearts.
Improvement in Cardiac Function by Rosiglitazone Was Not Associated With Increased Glucose Usage
Rosiglitazone is an insulin sensitizer that increases glucose catabolism. Thus, we tested whether rosiglitazone-mediated improvement in cardiac function of septic mice was accompanied by increased cardiac glucose catabolism. Glucose oxidation was reduced by 70% in C57BL6 mice that were treated with LPS and this defect was not attenuated by administration of rosiglitazone ( Figure 3F ). Accordingly, glucose transporter-4 (GLUT) mRNA levels were reduced (60%) in LPS-treated mice and were not increased by coadministration of rosiglitazone ( Figure 3G ). GLUT-1 mRNA levels did not change by any of the treatments ( Figure 3G ). PDK4 was increased 8-fold by LPS treatment and 4-fold in mice that received LPS and rosiglitazone as compared with salinetreated mice ( Figure 3G ), also indicating suppressed cardiac glucose usage. In addition, phosphorylated Akt levels were reduced in the hearts of LPS-treated mice, indicating inhibition of the insulin signaling pathway, which was not reactivated by rosiglitazone treatment ( Figure 3H ; Figure VII in the onlineonly Data Supplement). Plasma glucose levels were reduced in mice treated with either LPS or combination of LPS and rosiglitazone (CTRL, 130±10.6 mg/dL; Rosi, 93.6±4.9 mg/ dL**; LPS, 43±4.2 mg/dL****; LPS+Rosi, 50.3±2.5 mg/dL ¶ ; n=5; **P<0.01 versus CTRL; ****P<0.0001 versus CTRL; and ¶ P<0.01 versus Rosi). Thus, the rosiglitazone-mediated improvement in cardiac function of septic mice was not accompanied by restoration of glucose usage.
Rosiglitazone-Mediated Improvement of Cardiac Function in LPS-Treated Mice Was Not Associated With Cardiac Lipid Changes
Rosiglitazone administration along with LPS was still associated with increased cardiac TG content, although to a slightly less extent than was found in mice treated with LPS alone (Figure 2A ). This likely reflected the increased FAO driven by rosiglitazone, as circulating TG and FFAs were similar to those measured in LPS-treated WT mice ( Figure 2B and 2C ). CD36 mRNA levels were increased (7-fold) in mice treated with LPS and rosiglitazone, as compared with mice treated with LPS only ( Figure 2G ). Moreover, these data suggest that lipid accumulation, which is toxic in other circumstances, 17,28-30 was not the reason for LPS-mediated heart dysfunction.
Further evidence was obtained by measuring intracellular toxic lipids. Impaired usage and eventual intracellular accumulation of fatty acids are often accompanied by increased ceramide levels, which may account for cardiac dysfunction. 31, 32 Despite accumulation of TGs in the hearts of LPStreated C57BL/6 mice, liquid chromatography tandem mass spectrometry analysis of cardiac lipids showed that neither total ceramide levels ( Figure 2I ) nor any of the ceramide species that we tested ( Figure 2J ) were increased in septic animals. In addition, combination of LPS and rosiglitazone did not affect cardiac ceramide levels as compared with LPStreated mice ( Figure 2I and 2J) . Thus, both LPS-driven cardiac dysfunction and rosiglitazone-mediated improvement of cardiac function in LPS-treated mice were not associated with changes in ceramide levels.
Rosiglitazone-Mediated Improvement in Cardiac Function of Septic Mice Is Associated With Increased Cardiac Mitochondrial Number and Size
Mitochondria are the major site of substrate oxidation and ATP production in cardiomyocytes. Electron microscopy analysis (magnification, ×6000) revealed reduced number of mitochondria in cardiomyocytes of LPS-treated mice ( Figure 4A ; Figure VIIIA in the online-only Data Supplement). This observation was confirmed by the measurement of ATPase 6/β-actin DNA ratio, which was 30% lower in hearts of LPS-treated mice ( Figure 4B) , an additional indication of reduced number of mitochondria. Both electron microscopy ( Figure 4A ) and DNA analyses ( Figure 4B ) showed that combined treatment of mice with LPS and rosiglitazone prevented reduction of mitochondria. Analysis of the activity of mitochondrial enzymes showed that citrate synthase activity was reduced by 35% in LPS-treated mice and was restored to normal levels in septic mice that were treated with rosiglitazone ( Figure 4C) . Similarly, a 25% reduction was observed in cardiac complex IV activity by LPS treatment that was prevented in mice treated with LPS and rosiglitazone ( Figure 4D ). However, when complex IV activity was normalized to citrate synthase activity, no significant change was observed among all animal groups ( Figure 4E ). This observation indicates that the reduction in complex IV activity was likely because of the reduction in mitochondrial number. Thus, electron microscopy, DNA analysis, and mitochondrial enzyme activity assays showed that rosiglitazone prevented LPS-driven reduction of mitochondria.
Mitochondrial biogenesis is controlled by mitochondrial transcription factor A, 33, 34 which is regulated by PGC-1. 35 PGC-1 is important for the maintenance of healthy cardiac function under stressed conditions 3, 36 and is a central regulator of mitochondrial biogenesis. 19 PGC-1α and PGC-1β mRNA levels were reduced by 70% and 60%, respectively, in LPS-treated mice and restored by rosiglitazone treatment of septic animals ( Figure 4F ). Specifically, rosiglitazone administration in LPS-treated mice increased PGC-1α (5.3fold) and PGC-1β (4-fold) mRNA levels, as compared with mice treated with LPS only ( Figure 4F ). Moreover, PGC1-α mRNA levels were increased by 2.4-fold in mice that were treated with rosiglitazone alone, as compared with salinetreated mice ( Figure 4F ). Accordingly, cardiac mitochondrial transcription factor A mRNA levels were reduced by 50% in LPS-treated mice and treatment with rosiglitazone restored normal levels of mitochondrial transcription factor A in septic mice ( Figure 4F ). Further analysis of the electron microscopic photos showed that cardiomyocytes of LPS-treated mice had less area occupied by mitochondria as compared with Lipopolysaccharide reduced average mitochondrial size, which tended to be reversed in LPS-treated mice that received rosiglitazone ( Figure 4G ; Figure VIIIC in the online-only Data Supplement). Thus, LPS reduces cardiac mitochondrial number and size and the mitochondrial phenotype is rescued by rosiglitazone.
Autophagy is a cellular process that affects mitochondrial turnover 37 and is induced by LPS administration in cardiomyocytes. 38 Thus, we tested whether markers of autophagosome formation are modulated in the hearts of mice treated with LPS or combination of LPS and rosiglitazone. LPS administration increased mRNA levels of autophagyrelated genes, atg3 and atg5 ( Figure 4H ), whereas administration of rosiglitazone in LPS-treated mice normalized Atg3 and Atg5. However, Atg7, Atg10, and Beclin (Bcn) 1 mRNA levels were not significantly modulated in any of the tested treatments ( Figure 4H ). Protein analysis of LPS-treated hearts showed that septic mice had increased levels of Atg7 and microtubule-associated protein 1, light chain 3, β (LC3B) II, markers of autophagosome formation ( Figure 4I ; Figure IX in the online-only Data Supplement). These changes were prohibited when LPS-treated mice were coadministered rosiglitazone ( Figure 4I ; Figure IX in the online-only Data Supplement). Thus, autophagy, which may affect mitochondrial number, is induced in the starved hearts of septic mice and is normalized in mice treated with LPS and rosiglitazone.
Administration of Rosiglitazone After Induction of Sepsis With LPS Treats Cardiac Dysfunction
To assess whether rosiglitazone administration is a potential treatment for established sepsis-related cardiac dysfunction, C57BL/6 mice were injected intraperitoneally with 5 mg/kg LPS, and 30 mg/kg rosiglitazone was administered intraperitoneally 4 hours post-LPS injection, when cardiac dysfunction was confirmed by 2D echocardiography. Rosiglitazone restored normal cardiac function in all mice tested ( Figure 5A and 5B) . However, cardiac function of LPStreated mice that received vehicle (DMSO [dimethyl sulfoxide]) either did not improve or was even more aggravated ( Figure 5C and 5D ). Rosiglitazone did not alter cardiac function of saline-treated mice ( Figure 5E and 5F ). between 48 and 72 hours after injection. Daily administration of rosiglitazone reduced mortality ( Figure 5G ) and improved mobility and general appearance of the LPS-treated mice (Movies in the online-only Data Supplement).
Treatment With Rosiglitazone Improved Survival of LPS-Treated Animals
Discussion
Sepsis is a major cause of death in intensive care units. Approximately 25% of patients with severe sepsis have cardiovascular complications 39 and 30% of them are terminal. 1 Cardiac FAO is suppressed during sepsis as shown by analysis of myocardial pieces, 2 isolated perfused hearts, 3, 5 and cardiac homogenates. 4 Opposite to afterload-induced heart failure that FAO is reduced and glucose oxidation is increased, 40 our work and previous studies 3, 6 showed that LPS-mediated reduction cardiac FAO is not compensated by increased glucose catabolism. Thus, sepsis is accompanied by cardiac energy deficiency. Because either PPARα or PPARγ can stimulate cardiac FAO, 15, 41 we tested whether PPARγ activation compensates for LPS-mediated PPARα reduction and restores FAO and cardiac function. Constitutive cardiomyocyte expression and rosiglitazone-mediated activation of PPARγ improved FAO and prevented cardiac dysfunction in mice that were treated with LPS, although cardiac inflammation was not alleviated.
The high expressing transgenic line of αMHC-PPARγ has impaired cardiac function. 17 Therefore, we used the mediumexpressing line that has normal cardiac function to test whether constitutive cardiomyocyte expression of PPARγ prevents the detrimental effects of LPS on cardiac function. Despite the downregulation of PPARα by LPS, αMHC-PPARγ mice had normal cardiac FAO, ATP, and increased FAO-associated gene expression levels, as well as normal heart function. Similarly, rosiglitazone increased cardiac FAO and ATP, prevented cardiac dysfunction in LPS-treated mice, and improved survival when given after confirmation of septic cardiac dysfunction. Prevention of septic cardiac dysfunction in αMHC-PPARγ mice is associated with increased PGC-1α, Cpt-1β, PPARδ, and AOX mRNA levels. Rosiglitazone-mediated improvement in cardiac function of LPS-treated C57BL/6 mice is accompanied by increased PGC-1α, CD36, and Cpt-1β mRNA levels. The slightly different profile in gene expression changes between the 2 animal models may reflect differences between chronic (genetic model) and acute (pharmacological model) PPARγ activation in sepsis. It may also be because of the fact that pharmacological treatments are not totally specific and may also affect other tissues that, in turn, may alter cardiac gene expression profile. The gene expression profile was consistent with our previous findings showing that constitutive PPARγ expression can substitute for PPARα to maintain FAO. 15 PPARγ activation increases FAO more potently when PPARα is downregulated, but the underlying cellular mechanism remains unknown.
Although chronic PPARγ agonist administration has antiinflammatory effects especially in macrophages, 42 the PPARγmediated improvement in cardiac function of LPS-treated mice was not associated with attenuation of the expression of inflammatory markers in the heart during our short-term studies. This finding is consistent with our previous study showing that improvement in cardiac function by Jun-N-terminal kinase inhibition was not associated with alleviation of local cardiac inflammation. 2 These observations indicate that inflammation is not the major aggravating factor for sepsis-triggered cardiac dysfunction, at least at the early stages of the disease.
Rosiglitazone increased PGC-1α in saline and LPS-treated C57BL/6 mice. PGC-1 is a coactivator of cellular energy metabolism-related transcription factors, including PPARs 43 and a regulator of mitochondrial biogenesis. 19 A recent study showed that constitutive PGC-1 expression protects cardiomyocytes from LPS-mediated consequences 3 via improvement in FAO and reduction in reactive oxygen species production. Furthermore, our data show that the number and size of mitochondria were reduced in hearts of LPS-treated mice and rescued in septic animals that were treated with rosiglitazone. Reduction in mitochondrial number has also been reported in hearts of septic rats. 44 Mitochondrial turnover that is induced in LPS-treated cardiomyocytes 38 occurs via autophagy, 37 which is triggered by nutrient deprivation 45 and subsequent AMPK activation 46 that we also observed. Restoration of cardiac mitochondrial number in septic mice treated with rosiglitazone was associated with reduced levels of autophagy markers. Thus, the beneficial effect of rosiglitazone in the prevention of mitochondrial loss may be because of autophagy suppression.
In conclusion, we have found that PPARγ activation prevents LPS-mediated reduction in cardiac FAO and mechanical dysfunction, despite increased expression of inflammatory markers in the heart. Systemic administration of PPARγ agonist improves survival and overall appearance of LPS-treated mice. The findings of this and our previous study 2 suggest that compromised energy production rather than cardiac inflammation seems to be a critical factor for reduced cardiac function within the first hours of disease progression. A schematic representation of the proposed pathway that mediates the effects of sepsis on cardiac FAO and heart function, as well as the protective role of PPARγ, is in Figure 6 . LPS induces the production of inflammatory cytokines and suppresses PPARα and PGC-1 leading to compromised FAO and cardiac dysfunction. Impaired FAO is associated with triglyceride accumulation, increased autophagy, which in combination with PGC-1 downregulation leads to reduction in mitochondrial number. Activation of PPARγ compensates for LPS-mediated downregulation of PPARα and preserves FAO and cardiac function, despite continued inflammation. Besides heart, sepsis affects the function of multiple other organs. 47 The importance of defective metabolism versus inflammation in sepsis-induced dysfunction in these organs is unknown. The beneficial effects on heart function of septic mice by the acute treatment with rosiglitazone, which we observed in our study, contrast with those associated with chronic use of PPARγ agonist in patients with diabetes mellitus. 48 In these situations, PPARγ agonists are associated with increased heart failure, either because they increased salt and water retention 49 or because they directly affect heart function perhaps because of lipid toxicity. 17, 50 Nonetheless, our data implicate acute PPARγ-mediated induction of FAO as a treatment of sepsis that can be used in combination with antiinflammatory therapies to prevent dysfunction of the heart and possibly other organs. 
CLINICAL PERSPECTIVE
Sepsis is a major cause of death in critically ill patients and has been associated with impaired cardiac contractility and diastolic dysfunction that contribute to hypotension and increased mortality. Approximately 25% of patients with severe sepsis have cardiovascular complications and 30% of them are terminal. Cardiac dysfunction in sepsis is associated with both inflammation and reduced fatty acid oxidation. In contrast to chronic left ventricular dysfunction secondary to pressure-overload or ischemia, which show reduced fatty acid oxidation and increased glucose oxidation rates, septic cardiac dysfunction is characterized by general suppression of both FA and glucose usage for energy homeostasis. We hypothesized that cardiac dysfunction during sepsis is, at least in part, because of cardiac energy deficiency. Using an animal model of lipopolysaccharide-induced cardiac dysfunction, we show that left ventricular dysfunction is prevented by genetic or pharmacological activation of peroxisome proliferator-activated receptor-γ, treatments that improve fatty acid oxidation, while cardiac expression of inflammatory markers was not affected. Moreover, administration of rosiglitazone, a peroxisome proliferator-activated receptor-γ agonist, reduces mortality and improves overall frailty of septic mice. The beneficial effects of rosiglitazone are associated with improved cardiac fatty acid oxidation and reduced mitophagy. In conclusion, activation of peroxisome proliferator-activated receptor-γ in animals with sepsis increases myocardial energy production and improves cardiac function and survival.
